BMS’s Plans For Zeposia In Crohn’s Dubious Following Phase III Miss

 
• By Joseph Haas

The oral S1P modulator, approved to treat ulcerative colitis and MS, missed its primary endpoint in the first of two Phase III induction studies in moderate-to-severe Crohn’s disease.

Many arrows missed hitting target mark. Shot miss. Multiple failed inaccurate attempts to hit archery target. Business challenge failure metaphor. Flat cartoon isolated vector object illustration
Bristol Myers Squibb missed its Phase III endpoint in Crohn's with Zeposia • Source: Shutterstock

More from Clinical Trials

More from R&D